Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan For Launch Of Microcyn(R) Technology
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a progenitors of products based upon the Microcyn® Technology party line that is intended to treat infections in chronic and perspicacious wounds, announced that the Oculus happening team completed meetings this lifetime week in Beijing, China with Chinese partners at China Bao Tai and Sinopharm no matter what commercialization plans for the product launch of Microcyn Technology in China.
Oculus Innovative Sciences entered into an pact with China Bao Tai in 2007 in the interest the cataloguing of Microcyn-based products in China. The partnership allows Oculus and the Microcyn Technology to gain a foothold in China through China Bao Tai and its various sub-distributors, including Sinopharm and Lianhua Supermarket Holdings Co., Ltd.
The first phase of the Chinese commercialization plan includes sampling of Chinese fold care professionals with the Microcyn-based Dermacyn™ effect. This will initially target passkey opinion leaders via trials at multiple medical centers for the sake the purpose of securing both post-demand clinical figures and reimbursement. Dermacyn was approved in March of this year by the Chinese Report Food and Drug Activity (SFDA) as a technology that provides a moist setting for wounds and accelerates anguish healing from one end to the other the reduction of microorganisms in wounds.
In results from Oculus’ recently completed U.S. Phase II clinical dry run evaluating Microcyn® Technology as a topical antimicrobial treatment looking for mildly infected diabetic foot ulcers, the clinical star rate at the test-of-nostrum visit inasmuch as Microcyn-alone-treated evaluable patients was 93% compared to 56% in requital for the levofloxacin (antibiotic) plus saline-treated patients. This data, along with complementary results from more than 25 other additional Microcyn trials previously completed, is a key message because of the Chinese peddle since it indicates that Microcyn use can reduce the have need of for systemic antibiotics, the overuse of which is executive for the global wide-ranging of antibiotic-resistant bacteria and viruses such as MRSA.
Hoji Alimi, CEO and designer of Oculus said, “It is vital that the Microcyn Technology be politely positioned and its wide spectrum of potential applications fully communicated to the Chinese medical community. To that end, the Oculus team and our Chinese partners are crafting a runabout plan that is designed for short- and big-length of time prosperity, further underscoring our commitment to this important market-place. We believe this well-conceived, multi-tiered commercialization blueprint will require patients with the latest further in both anti-infective and muffle healing technologies and Oculus shareholders with the optimal return in this immense exchange of 1.3 billion people.”
Chinese Healthcare Market
According to Review of the American Medical Association, as is the case in much of the rest of the happy, the aged extent of China’s population is increasing. The population older than 65 years included 100.4 million persons, or 7.69% of China’s total inhabitants, in 2005 and is expected to burgeon at an annual grade of 3.28%. With this increased venerable population, total healthiness protect needs and expenditures will further as well. China’s proportion of GDP allocated to health attend to, currently about 5.55%, is indubitably to proliferating steadily to become closer to that of developed countries, most of which force comparable rates of 8% to 11%, up to nearly 16% in the Pooled States.
Decision Resources, one of the world’s leading research and consultive firms focusing on pharmaceutical and healthcare issues, finds that the prevalence of type 2 diabetes in China is staggering, rivaling that of the United States, Europe, and Japan combined. According to a new Emerging Markets-China reveal entitled Type 2 Diabetes in China, the prototype 2 diabetes psychedelic buy in China compel reach $1.3 billion in 2010. The report also finds that increasing economic power in China has led to growing numbers of patients with suppletive healthcare bond and an improved ability to sacrifice Western-branded drugs.
About China Bao Tai Investment Callers
China Bao Tai Investment Co., Ltd. is a diversified investment fellowship with a focus on health care, high-tech, new vim sources, and environmental safeguard. It is registered with the State Administration for the benefit of Earnestness and Mercantilism of the People’s Republic of China. China Bao Tai has extensive know introducing new products and technologies into China and enjoys a productive working relationship with both local and central government agencies. They will utilize various sub-distributors seeing that hospitals, non-partisan pharmacies and retail pharmacies. In that exploit, China Bao Tai has reached agreement with two key sub-distributors:
Sinopharm in return nursing home and druggist’s sharing
Sinopharm (http://www.sinopharm.com/en) is China’s largest pharmaceutical platoon. Incorporating research with production and navy trade, the company has under its bailiwick 10 exclusively owned subsidiaries or shareholding companies. In 2004, its sales returns from medicines and medical equipment totaled $2.3 billion US and its imports and exports volume reached $500 million US.
Lianhua Supermarkets for supermarket distribution
Lianhua Supermarket Holdings Co., Ltd. (http://www.lhok.com.cn) is a retail chain operator with retail outlets covering the entire Chinese nation, gift a full tier of products to command operations, franchises, mergers and acquisitions. Lianhua Supermarket operates a total of 3,609 outlets spanning 21 provinces and municipalities across the nation.
With Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prohibit and treat infections in lingering and acute wounds. The Microcyn Technology party line is a biocompatible, shelf-stable explanation containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform set up demonstrated, in a variety of research and investigational studies, the knack to therapy a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores.
A recently completed U.S. Status II clinical trial of Microcyn Technology met the primary endpoints of safeness and efficacy proper for the treatment of mildly infected diabetic foot ulcers.
Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan by its quite owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus’ website is http://www.oculusis.com.
Unabashed-Looking Statements
Except for factual news herein, some matters set forth in this prod salvation are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Renovate Act of 1995. These forward-looking statements are identified by the use of words such as “finalize,” “will,” “securing,” “communicated,” “designed,” and “will provide,” mid others. Forward-looking statements in this press emancipation are subject to undisputed risks and uncertainties inherent in the Company’s business that could cause verified results to vary, including risks inherent in the development and commercialization of imminent products, the risk that regulatory clinical and guideline developments may swop, the jeopardize that painstaking statistics may not be sufficient to meet regulatory standards or stub of required regulatory clearances or approvals, the risk that clinical results may not be replicated in actual patient settings, the risk that protection offered by our patents and self-evident applications may be challenged, invalidated or circumvented by our competitors, the risk that tender trends will continue and that the close by market by reason of our products will not be as gargantuan as expected, the chance that our products will not be skilled to penetrate one or more targeted markets, the risk that revenues will not be adequate to bread further development and clinical studies, the Company’s future initial needs, and its genius to obtain additional funding and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including the three-monthly report on Form 10-Q for the division ended December 31, 2007. Oculus Innovative Sciences disclaims any obligation to update these mail-looking statements.
Oculus, Microcyn and Dermacyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the capital goods of their respective owners.
Oculus Innovative Sciences
Best Ever Personal Training Guide
Influence loss as is the custom sees a colossal uptake at the initiate of the New Year. This seems to be the time for individuals to re-assess their lives in myriads disparate sectors and load loss has appropriate for on of the largest well known zones to address.
With popular and international obesity levels on the increase which in turn is important to more health related illness such as category 2 diabetes at once is the time to act to screen your health.
Lack of time is frequently an area which citizens struggle to perceive as been at one’s fingertips to exercise. This identified obstruction is regularly closely followed by lack of confidence.
Lack of metre is time and again associated with not being masterful to fit in formerly to visit the gym. Lack of conviction can be traced requital to quondam attempts where you may display lost weight and then regained it every a particular of back again with an increment of a little bonus.
Whichever noted barrier you wait in your wavering be decided, take some speedily out and really grill it, and look for creative ways to overwhelmed them i.e. Forget the gym and proceeds a walk during your lunch break. Be without of confidence, go into by reviewing what your commendable at, we every individual of have something and try to produce your belief for this, reminisce over confidence is developed with even-sided paltry steps in the right avenue.
Set into any reserve shop, Google heaviness loss or pick up any celebrity munitions dump and you will present, hear or see hundreds possibly thousands of solutions.
To be expected solutions eventually and again include a balanced diet and fitness training programme.
Swimming is often chosen as a low crashing and gaiety tariff to agitate to advise with weight loss.
Swimming reduces the impact upon joints these as your knees, hips and back whilst at the same time allowing you to mark aggressive up a satisfactory level cardiovascular eligibility and muscle tone.
Aquarobics classes grant develop a very favoured off race of old swimming. A run-of-the-mill An Aquarobics class may be liked very much to an Aerobics kind on out landing without the impact on the joints and less talk into for footwork to remember. Aquarobics classes are often court at regional relief facilities or more up market healthfulness clubs.
When your comparing the diverse bias loss programmes close by you should look for the inclusion of three elementary sectors; healthy eating, exercise and behaviour modification. If a performance contains these three quintessential aspects your chances of success are individual, if as a matter of actual fact it no longer becomes a befall so great as your ready mentally.
You own it to yourself to pinpoint the right approach. With it longing become public increased one’s self faith and better selfhood-account not to mention having the body and punch levels you require.
Maragret Boldizsar is a ace familiar trainer who guides people emotionally squander bias with bright pilates programmes. Her customers experience tremendous weight waste.
4 million extra health workers needed worldwide
Authors of a public-vigorousness article in this week’s issue of THE LANCET are calling for urgent international deed to address the chronic lack of investment in human resources which is limiting the chance of tackling diseases such as HIV/AIDS, malaria, and TB.
The Lancet article is an executive summary of a fuller report about human resources investment and global health being published by Harvard University Press. The key premise of the article and full report is that no amount of improvements in the development of new treatments and relative reduction in financial costs of health services can make the required impact unless there is a renewed investment in human resources—health-care workers—to deliver health services in the areas where they are most needed, especially in sub-Saharan Africa.
The Joint Learning Initiative—a consortium of more than 100 health leaders—proposes that mobilisation and strengthening of human resources for health, neglected yet critical, is central to combating health crises in some of the world’s poorest countries and for building sustainable health systems in all countries.
Co-author of the study Lincoln Chen (Harvard University, USA) explains: “Nearly all countries are challenged by worker shortage, skill mix imbalance, maldistribution, negative work environment, and weak knowledge base. Especially in the poorest countries, the workforce is under assault by HIV/AIDS, out-migration, and inadequate investment. Effective country strategies should be backed by international reinforcement. Ultimately, the crisis in human resources is a shared problem requiring shared responsibility for cooperative action.�
The authors highlight how 4 million extra health workers worldwide are needed if the required health improvements and millennium goals are to be met by 2015. Human resources in sub-Saharan Africa are singled out as a top priority: the authors estimate that this region needs to triple its current human resources infrastructure by creating one million extra workers to deliver health services, most of them at the community level.
Dr. Chen comments: “It is impossible to underestimate the importance of a response to this call for action. At stake is nothing less than completing the unfinished agenda in health of the past century while addressing the historically unprecedented health challenges of this new century. Millions of people around the world are trapped in a vicious spiral of sickness and death. For them there is no tomorrow without action today. Yet, much can be done through the rapid mobilisation of the workforce, and wise investments today can build a stronger human infrastructure for sustainable health systems. What we do—or what we fail to do—will shape the course of global health for the entire 21st century.�
http://ww.thelancet.com
Flax In Diet Means Fewer Tumors
Immature research from South Dakota State University offers evidence that including flax in the diet may help prevent colorectal tumors or shut in tumors from growing as quickly when they do envisage.
Distinguished professor Chandradhar Dwivedi, head of SDSU’s Department of Pharmaceutical Sciences, directed the study by departmental graduate student researchers Ajay Bommareddy, Xiaoying Zhang and expert doctor of pharmacy student Dustin Schrader.
“The reflect on was conducted in a special purify of mice that develop knee-jerk intestinal tumors fitting to mutation in a gene,” Dwivedi said.
“This model is developed to investigate the effects of cancer anticipatory agents on genetically predisposed individuals,” he said.
“Results indicated that mice on diets supplemented with flaxseed carry to extremes and flaxseed lubricant had, on average, 45 percent fewer tumors in the young intestine and the colon compared to the repress group.”
The scientists published their enquire findings in February in the conjectural match-reviewed international journal Nutrition and Cancer.
“The results show that tumors in dietary flaxseed-treated groups, not counting being few, were also very small in take the measure of when compared with what we found in the other experimental diets,” Dwivedi said.
The study has momentous implications for human health, since colorectal cancer is the third-matchless cause of cancer deaths in the United States. Aware statistics from the American Cancer Society showed that in 2008, 108,070 new colon and 40,740 revitalized rectal cases were diagnosed in the Common States, while colorectal cancers caused 49,960 deaths.
Flaxseed contains a exalted percentage of alpha-linolenic acid, omega-3 fatty acid, and lignans, a group of chemical compounds found in plants that enactment as antioxidants.
The up to date SDSU study builds on past research carried out of the closet by Dwivedi’s lab at SDSU looking at the chemopreventive effects of dietary flaxseed fuel and flaxseed repast on colon tumor development.
“Dietary flaxseed unguent and meal are effective chemopreventive agents against colon and intestinal tumor development in experimental animal models,” Dwivedi said.
“Further studies are needed to secure the optimal amount of flaxseed that should be incorporated into human diets to be given an anti-tumor benefit and to explore the possible machinery of action by which flaxseed can serve prevent colon cancer.”
Other participating researchers included allied professor Radhey Kaushik, who has a joint assignation in SDSU’s Department of Veterinary Sciences and the Department of Biology and Microbiology; professor David Zeman, head of the Department of Veterinary Sciences; and professor Duane Matthees of the Department of Veterinary Sciences.
The research was supported in put asunder give up by North Dakota Oilseed Council.
Source: South Dakota State University
First-Tme Mothers At Increased Risk For Postpartum Mental Disorders
New mothers are at an increased chance because of mental disorders such as schizophrenia, depression and bipolar disorder in the 3 months following the birth of their opening child, according to a review in the December 6 issue of JAMA. The study also found that firstly-on one occasion fathers do not have an increased peril for mental disorders.
Postpartum depression is a serious mental health problem owing women and their families, with an estimated prevalence of upon 10 percent to 15 percent among mothers. Postpartum disorders can also include more severe mental disorders, with a prevalence of about 1 per 1,000 births, according to history news in the article. There is some intimation that a small interest of men experience postpartum depression, but the possible relationship between becoming a father and first onset of mental disorders has not been established.
Trine Munk-Olsen, M.Sc., of the University of Aarhus, Denmark and colleagues conducted a study to estimate the jeopardize of postpartum screwy disorders requiring hospital admission or outpatient contact for victory-time mothers and fathers up to 12 months after becoming a foster-parent. The researchers analyzed matter from Danish health and secular employment registers, which as this study included a gross of 2,357,942 Danish-born persons who were followed up from their 15th birthday or January 1973, whichever came later, until date of onslaught of the disorder in question, meeting of death, date of emigration from Denmark, or July 2005, whichever came first.
From 1973 to 2005, a total of 630,373 women and 547,431 men became parents for the first sometimes. A total of 1,171 women and 658 men were admitted with a batty mishmash to a psychiatric nursing home during the start with 12 months after parenthood, and the corresponding prevalence of severe mental disorders past the first 3 months after childbirth was 1.03 per 1,000 births championing mothers and 0.37 per 1,000 births into fathers. For first-time mothers, the from the word go weeks and months after the delivery were associated with an increased imperil of first conceding with any mental pandemonium, and the period from 10 to 19 days following the birth was associated with the highest danger (7.3 times increased risk) compared with women who had delineated birth 11 to 12 months previously. The increased risk of admission among mothers remained statistically significant through the first 3 months after childbirth regardless of lifetime of the natural. Risk because of mothers was also increased because psychiatric outpatient contacts through the first 3 months after childbirth, also with the highest risk occurring 10 to 19 days following the birth.
Unlike motherhood, fatherhood was not associated with any increased peril of hospital admission or outpatient contact. “This may indicate that the causes of postpartum nuts disorders are more strongly linked to an altered physiological process coordinated to pregnancy and childbirth than psychosocial aspects of motherhood.”
“Accurate estimates of the rates of and risk factors for postpartum indentation are highly portentous for the scientific and clinical understanding of perceptual and behavioral disorders during the postpartum age as wholly as for planning mental salubrity services because of childbearing women and their families,” the authors jot.
—————————-
Article adapted by Medical News Today from unusual induce release.
—————————-
(JAMA. 2006;296:2582-2589.)
This study was supported by the Stanley Medical Research Institute, Chevy Run after, Md. Psychiatric epidemiological examine at the National Concentrate for Register-Based Research is in part funded through a collaborative concurrence with the Cluster for Basic Psychiatric Research, Psychiatric Sickbay, Aarhus, Denmark. Choose visualize the article because of additional report, including other authors, initiator contributions and affiliations, financial disclosures, funding and vouch for, etc.
Editorial: Postpartum Depression - A Major Viewable Salubriousness Difficulty
In an accompanying leading article, Katherine L. Wisner, M.D., M.S., of the University of Pittsburgh Medical Center, and colleagues comment on the findings concerning postpartum downheartedness.
“These collective data [Munk-Olsen et al and other studies] draw attention to the importance of recognizing childbearing as a mighty health factor in the compulsion movement of women. Childbearing influences the indubitably of any disease state and acts as a biopsychosocial factor that may facilitate new episodes of bug. The data also provide data to identify and support universal screening proper for postpartum well-disposed episodes. The studies converge on the dead for now frame of pre-eminent imperil for both hospitalization and outpatient contacts as the first 3 months postpartum, particularly in primiparae [first birth], independent of considerations of diagnosis,” they write. “Therefore, screening should be implemented as at daybreak as 2 weeks after delivery and no later than 12 weeks postpartum to single out episodes of major mood disorder and other mental illnesses.”
“Effective treatments for these episodes exist. Sudden implementation of treatment is careful because mood episodes can be lengthy and psychosocial sequelae increase with duration. Caring dent exacts a heavy toll on women’s functioning and the health and well-being of their children. … Mental health is crucial to a mother’s perspicacity to function optimally, enjoy relationships, modify also in behalf of the infant’s birth, and cope with the stresses and appreciate the joys of parenthood.”
(JAMA. 2006;296:2616-2618.)
Please see the editorial for the duration of additional information, including other authors, litterateur contributions and affiliations, financial disclosures, funding and support, etc.
Contact: Trine Munk-Olsen
JAMA and Archives Journals
Botox may reduce the incidence of keloids, improving the appearance of scars
Can a fresh-day drug cure an age-prehistoric healing fuss that causes more harm than the realistic injury?
Ongoing studies at Baylor College of Medicine in Houston are examining the use of botox and other medicines in reducing the incidence of keloids and improving the appearance of scars. Identifying the cause and cure for keloids, fibrous tissue outgrowths surrounding skin lesions and occurring most often in African-Americans, is almost as mystifying today as when they were first documented in ancient Egyptian times.
“If there is a lot of tension, activity or movement around the wound, there is a tendency for keloids to form,” said Dr. Anthony Brissett, assistant professor in the Bobby R. Alford Department of Otorhinolaryngology and Communicative Sciences and the study’s principal investigator as well as director of keloid clinics at BCM and the Harris County Hospital’s District’s Ben Taub General Hospital.
Researchers in the study, funded by the Mayo Foundation, are analyzing whether botox injections that “paralyze” the affected area may relieve enough tension to enhance healing and improve scars.
The slightest break in the skin - a mild scratch, an ear piercing or even a mosquito bite - can trigger an overabundance of scar tissue in people with keloids, which tend to occur above the neck and most often in dark-skinned individuals. The fibrous outgrowths continue to swell if untreated, causing pain, itching, and grotesque disfiguration.
Until a cure is found, current treatments may include the use of steroids, surgical excisions, silicone gel creams, radiation therapy, and customized pressure clips that hydrate the wound area. Brissett estimates that 60 to 70 percent of his patients respond favorably to a combination of these therapies although regular follow-up visits are vital – and lifelong, in many cases.
“The problem with keloids is that they are extremely difficult to treat,” said Brissett. “I tell my patients that this is a chronic problem and that we will see each other for treatments for the rest of our lives.”
Keloids are hardly rare: Brissett estimates that 5 to 15 percent of black populations suffer from them. For reasons that are still unclear, statistics show African-Americans are 15 times more likely to develop the disorder than people with lighter skin. Brissett, also the director of the Baylor Facial Plastic Surgery Center, hopes that greater attention will be devoted to keloid research, especially given the rising trend of cosmetic surgery among African-Americans and Hispanics in recent years.
“Keloids are an under-studied area,” said Brissett, “but now with an interest in tissue engineering and wound healing, with more of a cosmetic-type focus and a scientific approach to tissue engineering, we are noticing that people are beginning to identify various models of wound-healing.”
http://www.bcm.edu
Amifostine makes radiation more effective
Doctors in Brazil have concluded that the drug amifostine eases innumerable of the most common side effects associated with patients receiving radiation therapy to care of their cancer while simultaneously making the cancer more susceptible to radiation.
The study was published in the March 1, 2006, issue of the International Journal of Radiation Oncology-Biology-Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
The researchers set out to evaluate, via a clinical investigation of already published work, whether adding amifostine to radiation therapy would prevent common side effects, such as mouth dryness, difficulty swallowing, lung inflammation, bladder inflammation, problems with the esophagus and inflammation of the mucous membranes. In some cases, these side effects can be severe enough that the patients’ treatment has to be suspended or stopped completely – potentially preventing their cancer from being completely cured. The other major purpose of the study was to discover if amifostine would inadvertently protect the tumor from radiation.
The investigators narrowed their research to 14 randomized, controlled trials in which 1,451 patients were split into two groups: one receiving radiation therapy alone and the second receiving radiation therapy in addition to amifostine. Patients taking amifostine were shown to have less radiation-related side effects. The research also showed that the drug did not protect the tumor from the radiation therapy and patients receiving the drug were more likely to have their cancer affected by the radiation than patients not given amifostine.
Taking amifostine does have some drawbacks, with nausea and vomiting being the most common side effects reported. However, the doctors generally were able to control the side effects with anti-nausea medicine.
“Our research shows that adding amifostine to radiation therapy helps reduce side effects while at the same time making the radiation treatments more effective at killing the cancer cells,� said Andre Deeke Sasse, M.D., a radiation oncologist at Nucleo Brasileiro de Oncologia Baseada em Evidencias in Sao Paolo, Brazil. “We recommend that patients undergoing radiation therapy for cancer ask their doctor about adding amifostine to their treatment.�
http://www.astro.org
Repligen Announces Publication Of Positive Results With Proprietary HDAC Inhibitor In Huntington’s Disease Model
Repligen Corporation
(Nasdaq: RGEN) reported publication of a preclinical study
demonstrating that a novel histone deacetylase (HDAC) inhibitor improved
disease symptoms in a transgenic animal model of Huntington’s blight. The
look at, led by scientists at The Scripps Digging Institute, demonstrated
that verbal administration of the drug applicant to the mice after the sally
of symptoms slowed the advance of bug. Treated animals showed
select motor performance by multiple measures, reduced loss of body
importance, reduced brain atrophy and improved overall appearance compared to
untreated animals. Huntington’s mice were also analyzed fitted changes in the
hundreds of genes whose emotion in the brain is altered in the mouse
variety of Huntington’s, as well as in humans with Huntington’s disease.
Using gene microarrays, the researchers identified genes in three discernment
regions whose expression was altered in the Huntington’s mice and whose
mien was altered by treatment with the HDAC inhibitor. Treatment
degree normalized the expression open of take 90% of these
genes with 32% being restored to normal levels. These results support that
an HDAC inhibitor may be useful in treating Huntington’s malady and that
specific genes may be useful as biomarkers in clinical trials. The research
was conducted using a compound that is covered by Repligen’s exclusive
permit from The Scripps Research Organization. The chew over entitled “The HDAC
Inhibitor 4b Ameliorates the Disease Phenotype and Transcriptional
Abnormalities in Huntington’s Disease Transgenic Mice” will be published
the week of September 15, 2008 in the online interpretation of the Proceedings of
the National Academy of Sciences.
“The remarkable reduction in symptoms achieved in the Huntington’s sickness
model without overt toxicity defines a secondly disease end in favour of our HDAC
inhibitor program,” stated Walter C. Herlihy, President and Chief Executive
Political appointee of Repligen Corporation. “We plot to carry on to evaluate the
utility of our tale HDAC inhibitors as a potential treatment for both
Friedreich’s ataxia and Huntington’s murrain.”
Huntington’s disease is caused by a trinucleotide repeat expansion in
the Huntington’s contagion gene (Htt) that results in production of a mutant
misfolded protein that is unable to job correctly. Huntington’s
infection is characterized by dysregulation in the transcription of hundreds
of genes in the brain, foremost to Huntington’s symptoms ranging from jerky
and random movements to impaired point of view and perception. Huntington’s
bug is a familial disorder, passed from parent to child wholly a
modification in the normal gene. Symptoms of Huntington’s disorder typically
emerge between the ages of 30 and 50 and fall into three categories: motor,
cognitive and psychiatric. Cognitive symptoms comprise slowed processing of
intelligence in the brain, resulting in communication and planning
difficulties, while depression is the most common psychiatric symptom of
Huntington’s illness. Motor symptoms include lack of coordination, muscle
spasms, and chorea. As the disease progresses, any function requiring
muscle in check is affected, matchless to tough disability, incapacitation or
loss of life satisfactory to complications 10 to 20 years after symptoms oldest
appear. There are approximately 30,000 people in the United States with
Huntington’s disease and there is currently no safe and effective treatment
exchange for the illness.
Repligen licensed the aristocratic rights to authority property
covering HDAC inhibitors from The Scripps Research Institute in April 2007
following which Repligen established a HDAC development program for
Friedreich’s ataxia. As a remainder the past year, the Company has made weighty
progress in advancing this program, resulting in the identification of
advanced lead compounds with improved potency and specificity. These lead
compounds are currently being assessed in pharmacology and toxicology
models in request to determine if one is suitable for clinical development.
In addition to Huntington’s disease, Repligen is evaluating this species of
compounds for activity in preclinical models of other neurodegenerative
diseases including spinal burly atrophy.
About The Scripps Research Institute
The Scripps Research Commence is one of the world’s largest
independent, non-profit biomedical up on organizations, at the forefront
of basic biomedical proficiency that seeks to grasp the most law
processes of life. Established in its current configuration in 1961, it
employs approximately 3,000 scientists, postdoctoral fellows, scientific
and other technicians, doctoral inch by inch graduate students, and
administrative and technical support personnel and is headquartered in La
Jolla, California.
With respect to Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the
improvement of original therapeutics for neurological disorders. In addition,
we are the world’s leading supplier of recombinant Protein A, the sales of
which incompletely fund the advancement of our growth pipeline while
supporting our pecuniary stability. Repligen’s corporate headquarters are
located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.
Additional information may be requested from http://www.repligen.com.
This press release contains up-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Sample 21E of the Securities Exchange Take of
1934, as amended. The forward-looking statements in this release do not
constitute guarantees of subsequent performance. Investors are cautioned that
statements in this meet release which are not strictly historical
statements, including, without limitation, statements in spite of course or
future monetary fulfilment and position, management’s strategy, plans and
objectives for future operations, plans and objectives for the treatment of consequence
development, plans and objectives in the service of this point in time and unborn clinical trials
and results of such trials, plans and objectives for regulatory confirm,
legal remedy, thought-provoking property, product development, manufacturing plans
and performance such as the anticipated growth in the monoclonal antibody
market and our other target markets and projected evolution in product sales,
constitute forward-looking statements. Such unabashed-looking statements are
subject to a horde of risks and uncertainties that could cause actual
results to part company greatly from those anticipated, including, without
limitation, risks associated with: the celebrity of known and future
collaborative relationships, the Stock Exchange acceptance of our products, our
ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our slip someone a Mickey Finn development
programs, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Chow and Drug Administration
regulations, our facility to obtain, maintain and keep intellectual
property rights for our products, the risk of litigation concerning our
thinker property rights, our limited sales and manufacturing
capabilities, our dependence on third-party manufacturers and value added
resellers, our ability to hire and retain skilled personnel, our volatile
stock penalty, and other risks detailed in Repligen’s filings with the
Securities and Exchange Commission. Repligen assumes no constraint to
update any forward-looking advice contained in this press let off or
with respect to the announcements described herein.
Repligen Corporation
http://www.repligen.com
Can you Treat Candia using Pills and Over the Counter Medications?
Candida albicans is yeast that occurs in the gut of humans and it is the prime cause of yeast infections. When the activity of candida increases beyond tolerable limits, it results in yeast infections.
The normal route that people take to treat their yeast infection is to take over the counter drugs and medications. Unfortunately it is also common to find that these people never cure their yeast infections permanently and always have recurring episodes of yeast infections with increased severity.
By nature, we have helper bacteria present in our gut that keeps the candida in check. But due to certain conditions like taking antibiotics or pregnancy or other disease, when the body’s immunity is lowered resulting in an excessive candida activity and yeast infections.
Antibiotics and pills that are sold do more harm thatn good. Taking antibiotics prescribed for treatment will kill the helper bacteria that keep candida at check. Thus over the counter medications are the ones that need to be completely stayed away from if you want a permanent cure to yeast infections.
In natural method of treating yeast infections, the external infections are treated topically and at the same time, an anti candida diet needs to be followed which will not only stop the yeast infection symptoms immediately but also stop the recurring yeast infections to give you a permanent relief in a very short time. To Cure Penis yeast infection forever by means of a Simple Effective Permanent Natural Cure, Visit Yeast Infection Cure You will Discover how to get rid of even Severe Yeast Infection forever and stay away from those embarrassing itches and burns by treating the Root cause of the infection right away in 12 Hours! Sandra Greene, an ex-yeast infection sufferer had compared the best treatments available to help you Get Rid of Yeast Infections forever!
San Francisco Chronicle Examines Experimental Stem Cell Therapy For HIV-Positive People
The San Francisco Chronicle on Friday examined an unfolding clinical trial that combines components of genetic engineering, gene therapy and against cell digging to develop a “parallel unaffected system” for HIV-despotic people. More than 70 HIV-unqualified people are participating in the study — led by Ronald Mitsuyasu, director of the University of California-Los Angeles’ Center by reason of Clinical AIDS Analyse and Cultivation — half of whom received their own blood cells fortified with a gene that blocks HIV, and half of whom received a placebo at the start of the inquisition. According to the Chronicle, the trial seeks to amplify fortified blood cells that will block HIV infection of individual cells and eventually outlast natural blood cells so the long-suffering “would be left with a rebuilt immune system resistant to HIV.”
Study Details
The “secret” of the experimental gene therapy method to controlling HIV is a “custom-built” version of an enzyme called a ribozyme, developed by Australian researchers, that cuts up one of the virus’s nine genes when it attempts to replicate, the Chronicle reports. Because the body does not naturally produce the ribozyme, researchers began using stem cells — specifically those found in bone marrow and the bloodstream — to manufacture the enzyme. The type of stem cell — which is known as “the mother of all blood cells” because it develops into “the many kinds of white cells that fight infection” — is often a “target” of HIV, the Chronicle reports. To transfer the fortified cells into the body, participants in two, eight-hour sessions are connected to a machine that filters stem cells from their blood and then returns the blood. In the laboratory, a mouse virus engineered to carry the ribozyme gene — which “tell[s] the cell[s] how to make the enzyme” — is injected into the cells. After three days participants’ own stem cells, containing the ribozyme gene, are injected back into their body. In the following weeks, the stem cells produce white blood cells containing the ribozymes.
Reaction
Mitsuyasu said he does not think this treatment will become a substitute for antiretroviral drugs. However, “if we are intelligent in how we use the drugs with these immune therapy approaches, it could lead to extremely effective control of HIV,” he said. The trial’s preliminary results are expected to be ready in February 2007. UCLA and a research company in Sydney, Australia, owned by Johnson & Johnson currently are conducting similar trials (Russell, San Francisco Chronicle, 4/7).
“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.